Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Claims 1-15 and 17-23 are pending in the application. Claim 20 is rejected. Claims 1, 10-13 and 18-20 are objected to. Claims 2-9 and 14-17 are allowed.
Priority
This application is a 35 U.S.C. § 371 National Stage Filing of International Application No. PCT/US22/72793, filed on June 7, 2022, which claims benefit of Provisional Application No. 63/197,809, filed on June 7, 2021.
Information Disclosure Statement
The Information Disclosure Statement(s) (IDS) filed on December 14, 2023, January 22, 2024, March 21, 2025 and December 3, 2025 are in compliance with the provisions of 37 CFR 1.97 and 1.98. Accordingly, the Examiner has considered the IDS documents and signed copies of the 1449 forms are attached.
Claim Objections
Claim 1, 10-13 and 18-20 are objected to because of the following informalities:
Claim 1 should be amended to replace “-C1-10 alkylene-” with -C1-10 alkylene- for sake of consistency. See second line of variable L1 definition on page 2.
Claim 10 should be amended to replace “-C1-10 alkylene-” with -C1-10 alkylene- for sake of consistency.
Claim 11 should be amended to replace “-C1-10 alkylene-” with -C1-10 alkylene- for sake of consistency.
Claim 12 should be amended to replace “-C1-10 alkylene-” with -C1-10 alkylene- for sake of consistency.
Claim 13 should be amended to replace “-C1-10 alkylene-” with -C1-10 alkylene- for sake of consistency.
Claim 18 should be amended to replace “a compound of claim 1” with -the compound of claim 1- for sake of clarity and consistency.
Claim 19 should be amended to replace “a compound of claim 1” with -the compound of claim 1- for sake of clarity and consistency.
Claim 20 should be amended to replace “wherein tauopathy” with -wherein the tauopathy- for sake of clarity and consistency.
Appropriate correction is required.
Claim Rejections - 35 USC § 112(b)
The following is a quotation of 35 U.S.C. § 112(b):
(b) CONCLUSION — The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. § 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claim 20 is rejected under 35 U.S.C. § 112(b) or 35 U.S.C. § 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. § 112, the applicant), regards as the invention.
Claim 20 recites “Lytico-bodig disease (Parkinson-dementia complex of Guam)” on the fourth and fifth line of the claim and is rejected as indefinite. It is unclear whether Applicant intended “Parkinson-dementia complex of Guam” to further limit “Lytico-bodig disease.” It is suggested Applicant cancel the parenthetical limitation from the claim to overcome this issue of indefiniteness.
Allowable Subject Matter
Claims 2-9 and 14-17 are allowed.
The instant claims are allowable over the prior art. In the interest of compact prosecution, the Examiner made an attempt, on February 4, 2026, to telephonically reach CALEB A BATES but did not result in addressing the above claim objections and rejection.
Conclusion
Claims 1-15 and 17-23 are pending in the application. Claim 20 is rejected. Claims 1, 10-13 and 18-20 are objected to. Claims 2-9 and 14-17 are allowed.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to DAVID SHIM whose telephone number is (571)270-1205. The examiner can normally be reached Monday - Friday, 9 AM - 5 PM EST.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, RENEE CLAYTOR can be reached at (571)272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/D.M.S./Examiner, Art Unit 1626
/REBECCA L ANDERSON/Primary Examiner, Art Unit 1626
Prosecution Insights